Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLT PET/MR to Predict Graft Failure and GVHD in BMT
NCT03546556Phase 1Terminated
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Jan 2017
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of fluorothymidine F-18 in graft-versus-host disease (GVHD) and Graft failure (2 arms), sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoints: Overall FLT-PET Bone Marrow Signal at 35 days and Overall FLT-PET Signal Intensity within Host Secondary Lymphoid Sites at 100 days. Started Jan 2017; status: terminated.
02
Drugs
fluorothymidine F-18
03
Conditions
graft-versus-host disease (GVHD)Graft failure
Beyond the preview
Go deeper on NCT03546556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03546556.